Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.91 USD

1.91
684,092

+0.14 (7.91%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1.92 +0.01 (0.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Varian (VAR) Buys Noona to Boost Oncology Software Services

by Zacks Equity Research

Varian's (VAR) latest move provides it significant exposure to the cloud-based oncology services market.

    Accuray's (ARAY) Radixact System Used First Time in Germany

    by Zacks Equity Research

    Accuray's (ARAY) flagship radiotherapy systems have lucrative prospects.

    Accuray's CyberKnife Manages Prostate Cancer Effectively

    by Zacks Equity Research

    Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.

      Sreyoshi Mukherjee headshot

      3 Stocks to Watch as Bots Take Bigger Strides in US Healthcare

      by Sreyoshi Mukherjee

      Robotics and mechatronics shape up the U.S. medical industry; three stocks that catch the eye.

        Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y

        by Zacks Equity Research

        Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.

          Accuray's Radixact Gets AERB Nod in India, Prospects Solid

          by Zacks Equity Research

          The Atomic Energy Regulatory Board (AERB) approves Accuray's (ARAY) Radixact X9 in India; exposes the company to AI and Mechatronic trends.

            New Strong Sell Stocks for June 11th

            by Zacks Equity Research

            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

              Here's Why You Should Sell Accuray (ARAY) Stock Right Now

              by Zacks Equity Research

              Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).

                New Strong Sell Stocks for June 4th

                by Zacks Equity Research

                Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                  Accuray (ARAY) Down 13.7% Since Earnings Report: Can It Rebound?

                  by Zacks Equity Research

                  Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    New Strong Sell Stocks for May 23rd

                    by Zacks Equity Research

                    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                      New Strong Sell Stocks for May 11th

                      by Zacks Equity Research

                      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                        New Strong Sell Stocks for May 9th

                        by Zacks Equity Research

                        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                          Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top

                          by Zacks Equity Research

                          Radixact System and major software overhaul drive Accuray (ARAY) in Q3.

                            Accuray Radixact Picked by India's Apollo for Cancer Treatment

                            by Zacks Equity Research

                            Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.

                              Accuray's CyberKnife Treats First Patient at Erasmus MC

                              by Zacks Equity Research

                              Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.

                                Accuray Banks on Acquisition & Partnership Amid Competition

                                by Zacks Equity Research

                                Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.

                                  Varian Medical Receives Regulatory Nod for Sirtex Buyout

                                  by Zacks Equity Research

                                  The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.

                                    Sanghamitra Saha headshot

                                    Here's Why Small-Cap HealthCare ETFs & Stocks Are Good Picks

                                    by Sanghamitra Saha

                                    Two reasons why small-cap healthcare stocks and ETFs could be winners in the coming days.

                                      Accuray Gains on Radixact Unit, Solid Geographical Foothold

                                      by Zacks Equity Research

                                      Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).

                                        Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session

                                        by Zacks Equity Research

                                        The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.

                                          Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?

                                          by Zacks Equity Research

                                          Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up

                                            by Zacks Equity Research

                                            Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.

                                              Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid

                                              by Zacks Equity Research

                                              Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.

                                                athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4

                                                by Zacks Equity Research

                                                Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.